Introduction
In large clinical trials in patients with type 2 diabetes at high cardiovascular risk, three different sodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of heart failure (HF) hospitalization. [1] [2] [3] This beneficial effect was observed soon after randomization, suggesting a mechanism or mechanisms of action different from those usually considered with conventional glucose-lowering therapies. [4] [5] [6] [7] [8] In addition to a diuretic-haemodynamic action, effects on myocardial metabolism, ion channels, fibrosis, adipokines and uric acid have also been proposed. Many of these actions could also be beneficial in HF patients without diabetes. The renal protection afforded by SGLT2 inhibitors is also clearly relevant in all patients with HF. 9 Consequently, several trials have been designed to prospectively evaluate the efficacy and safety of SGLT2 inhibitors in patients with established HF, both with and without diabetes. 10 Here we describe the baseline characteristics of participants in the Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial.
Methods
DAPA-HF is a randomized, double-blind, controlled trial in patients with chronic HF with reduced ejection fraction (HFrEF), evaluating the effect of dapagliflozin 10 mg once daily, compared with placebo, in addition to standard care, on the risk of worsening HF and cardiovascular death. The trial is registered as ClinicalTrials.gov Identifier: NCT03036124 and the design has been published in full. 10
Summary of DAPA-HF design Patients
Men and women aged ≥ 18 years with HF are eligible if they are in New York Heart Association (NYHA) functional class ≥ II, have a left ventricular ejection fraction (LVEF) ≤ 40%, are optimally treated with pharmacological and device therapy for HF, and willing to provide written informed consent. In addition, patients must have a N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration ≥ 600 pg/mL if not hospitalized for HF within the previous 12 months or ≥ 400 pg/mL if hospitalized for HF within the previous 12 months. Patients with atrial fibrillation or atrial flutter must have a level ≥ 900 pg/mL, irrespective of history of HF hospitalization.
Key exclusion criteria include: type 1 diabetes mellitus, symptoms of hypotension or systolic blood pressure < 95 mmHg, recent worsening HF or other cardiovascular events or procedures (or planned procedures), estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m 2 (or rapidly declining renal function), and other conditions likely to prevent patient participation in the trial or greatly limit life expectancy. A full list of exclusion criteria is provided in the design paper. 10
Treatment of heart failure
Patients were required to receive standard drug and device therapy for HFrEF, in accordance with recognized guidelines, including: (i) an angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker (ARB), or sacubitril/valsartan, and (ii) a beta-blocker, unless contraindicated or not tolerated, as well as (iii) a mineralocorticoid receptor antagonist (MRA), if considered appropriate. 
Study visits and follow-up
After provision of informed consent, visit 1 started a 14 ± 7 day enrolment period during which the trial inclusion and exclusion criteria were checked, and baseline information was collected (including from clinical examination and laboratory measurements). Visit 2 was the randomization visit at which further assessments were conducted and study drug was dispensed. After randomization, follow-up visits took place at 14 and 60 days, with a particular focus on assessment of HF and volume status, adverse events, and checking blood chemistry, and then at 120, 240, and 360 days and 4 monthly thereafter, as detailed in the design paper. 10
Outcomes
The primary objective is to determine whether dapagliflozin is superior to placebo, when added to standard care, in reducing the incidence of a worsening HF episode (hospitalization or the equivalent, i.e. an urgent HF visit) or cardiovascular death, analysed as time-to-first event. The first of the secondary outcomes is the composite of HF hospitalization or cardiovascular death. The additional secondary outcomes are described in the design paper. 10
Statistical considerations
The underlying statistical assumptions in DAPA-HF are described in the design paper and details of the statistical approach to the analysis of subgroups, including patients with and without diabetes, are given in the online supplementary Methods S1. 10
Definition of diabetes and pre-diabetes in DAPA-HF
History of diabetes was provided by investigators. In patients without a history of diabetes, previously undiagnosed diabetes was defined as a glycated haemoglobin (HbA1c), measured in a central laboratory, of ≥ 6.5% at both visit 1 and visit 2. Among patients without known or undiagnosed diabetes, pre-diabetes was defined as a HbA1c ≥ 5.7% at visit 1 or visit 2. The remainder of patients, with a HbA1c < 5.7% at both visit 1 and visit 2, were defined as normoglycaemic (euglycaemic).
Comparator registries
Three recent registries encompassing Europe, Asia and the United States of America (USA) were used for comparison of patients in DAPA-HF with the so-called 'real-world' cohorts. [11] [12] [13] [14] [15] [16] [17] 
Comparator trials: summary of inclusion/exclusion criteria
We compared the baseline characteristics of patients in DAPA-HF with a number of recent randomized controlled trials. [18] [19] [20] [21] Two of these had broad inclusion criteria and are shown in the Results section; two more had restricted inclusion criteria (e.g. both included only patients in sinus rhythm and one only those with an ischaemic aetiology) and are shown in the online supplementary Methods S1.
PARADIGM-HF and ATMOSPHERE
The inclusion and exclusion criteria for the Prospective comparison of Angiotensin Receptor neprilysin inhibitors with Angiotensin 18, 19 Patients were eligible at screening if: ≥18 years, NYHA class II-IV, LVEF ≤ 35% (changed from ≤ 40% in PARADIGM-HF by amendment), elevated natriuretic peptide level, taking an ACE inhibitor or ARB, beta-blocker (unless contraindicated or not tolerated) and MRA, if indicated. The natriuretic peptide eligibility criteria were: BNP ≥ 150 pg/mL or NT-proBNP ≥ 600 pg/mL; patients hospitalized in the preceding 12 months were eligible with a lower level: BNP ≥ 100 pg/mL or NT-proBNP ≥ 400 pg/mL. Exclusion criteria included symptomatic hypotension or systolic blood pressure < 95 mmHg (< 90 mmHg in ATMOSPHERE), and eGFR < 30 mL/min/1.73 m 2 (< 35 mL/min/1.73 m 2 in ATMOSPHERE).
Results
The first patient enrolment visit took place 8 February 2017 and the first randomization occurred 15 February 2017. Subsequent recruitment in DAPA-HF was rapid, and randomization was completed 17 August 2018, with 4774 patients randomized at 410 sites in 20 countries. Failure (CHAMP-HF) registry was 59%, compared with 60% in DAPA-HF. The mean eGFR in CHAMP-HF was 60 mL/min/1.73 m 2 , which was lower than in DAPA-HF (66 mL/min/1.73 m 2 ) but the fraction of patients with an eGFR < 60 mL/min/1.73 m 2 was lower in CHAMP-HF than in DAPA-HF (26% vs. 41%). The use of conventional, evidence-based, disease-modifying therapy was greater, overall, in DAPA-HF than in the registries ( Table 1 and Figure 1) . The newer treatments, ivabradine and sacubitril/valsartan, were each used in a small minority of patients, both in the registries and in DAPA-HF (Table 1 ). However, the use of sacubitril/valsartan in DAPA-HF varied greatly by geographical region: 32.3% in North America, 24.5% in Western Europe, 6.9% in Latin America, 5.4% in Asia, and 2.7% in Central/Eastern Europe. Table 2 shows a comparison of key patient characteristics in two recent HFrEF trials (PARADIGM-HF and ATMOSPHERE) with DAPA-HF. Patients in DAPA-HF were, on average, somewhat older (mean 66 years) than in the other two trials. The percentage of females was similarly small in all trials. DAPA-HF and ATMO-SPHERE enrolled more Asians than PARADIGM-HF.
DAPA-HF compared with contemporary heart failure with reduced ejection fraction registries

DAPA-HF compared with other recent heart failure with reduced ejection fraction trials
*includes sacubitril/valsartan + required by protocol
Heart failure characteristics
A larger proportion of patients in DAPA-HF were in NYHA functional class III/IV (32%) than in PARADIGM-HF or ATMOSPHERE (24% and 28%, respectively). The average Kansas City Cardiomyopathy Questionnaire (KCCQ) overall and clinical summary scores were lower in DAPA-HF, reflecting the NYHA class distributions in the trials. Left ventricular ejection fraction was slightly higher in DAPA-HF than in the other two trials whereas NT-proBNP levels were broadly similar in all three trials. Heart rate and blood pressure were similar in each of the trials.
The percentage of patients with prior HF hospitalization was substantially smaller in DAPA-HF (47%) than in the other two trials (63% PARADIGM-HF and 60% ATMOSPHERE). In DAPA-HF, 16.4% of patients had been hospitalized for HF in the previous 6 months and 27.3% in the previous year.
The fraction of patients with an ischaemic aetiology was similar across the three trials. percentage of patients with a history of diabetes was higher in DAPA-HF (42%) than in PARADIGM-HF (34%); the fraction in ATMOSPHERE was lower because of the exclusion of patients with diabetes part-way through enrolment. 19 The proportion of patients with previous myocardial infarction and prior coronary revascularization was similar in the three trials and reflected the prevalence of ischaemic aetiology. The percentage of patients with a history of hypertension and prior stroke was slightly higher in DAPA-HF, compared with the other trials. The proportion of participants with atrial fibrillation/flutter on their electrocardiogram was similar across trials. Mean eGFR was lowest, and the fraction of patients with an eGFR < 60 mL/min/1.73m 2 was highest, in DAPA-HF (see Discussion section). Overall, 28% of men and 26% of women in DAPA-HF had anaemia, a slightly higher proportion than in the other two trials.
Past history and co-morbidity
Baseline drug and device therapy
Beta-blocker use was higher in DAPA-HF than in any prior trial (Figure 1) , whereas digoxin use was less than in the other trials. The rate of use of an MRA was very high in DAPA-HF (71%) compared with PARADIGM-HF (60%) and ATMOSPHERE (37%). Overall, 10.8% of patients in DAPA-HF were treated with sacubitril/valsartan at baseline and 4.8% with ivabradine. The percentage treated with ivabradine was 1.0% in ATMOSPHERE and 1.5% in PARADIGM-HF.
The proportion of patients in DAPA-HF with an implantable cardioverter-defibrillator (ICD) was larger than in either of the previous trials. 
Comparison of patients with and without diabetes
Of all patients randomized, 1983 (42%) had a pre-existing diagnosis of diabetes and 154 a HbA1c in the diabetes range at visit 1 and visit 2, i.e. the total number with known or undiagnosed diabetes was 2137 (45%). The baseline characteristics of these two groups are shown in Table 3 and discussed further below.
Of the 2607 patients without diabetes, 1750 had pre-diabetes (67% of those without diabetes and 37% of all randomized participants) and 857 a normal HbA1c (33% and 18%, respectively). The baseline characteristics of these two groups, as well as patients with diabetes, are shown in the online supplementary Table S2 . Patients with pre-diabetes were older than individuals with a normal HbA1c but were otherwise more similar to euglycaemic patients than patients with type 2 diabetes.
Heart failure characteristics
Patients with pre-diabetes and diabetes had worse KCCQ scores than those without diabetes and the NYHA class distribution was worse in patients with diabetes.
The proportion of patients with an ischaemic aetiology was higher in those with diabetes (62%) than in those without. Mean LVEF was similar in both groups but NT-proBNP was higher in patients with diabetes. Heart rate was similar in the two groups but blood pressure (and the percentage with an elevated blood pressure) was highest in patients with diabetes.
The proportion of patients with a prior HF hospitalization did not differ greatly between the groups.
Past history and co-morbidity
Median body mass index and the fraction of obese patients increased significantly between those with and without diabetes (44% and 28%, respectively).
The proportion of patients with a history of myocardial infarction and coronary revascularization was higher in patients with diabetes, in keeping with the fraction of patients with an ischaemic aetiology. The percentage of participants with a history of hypertension differed in a similar way, consistent with baseline blood pressure. Investigator-reported co-morbidities collected in DAPA-HF, additional to those collected in the other trials, were foot ulcer, amputation, neuropathy and sleep apnoea. Each of those was uncommon but more frequent in patients with a history of diabetes, although were also reported in a few patients without diabetes.
Mean eGFR was lower, and the proportion of patients with an eGFR < 60 mL/min/1.73 m 2 higher, in those with diabetes compared to no diabetes, with 46% of patients in the former group categorized as having chronic kidney disease. The percentage of patients with anaemia was also highest among those with diabetes (33.6% of men and 28.0% of women).
Baseline drug and device therapy for heart failure
A similar fraction of patients in each group was treated with a renin-angiotensin system blocker, beta-blocker, a MRA and devices [ICD and cardiac resynchronization therapy (CRT)]. The highest rate of use of digoxin was in the diabetes group.
Baseline therapy for diabetes
In patients with a pre-existing diagnosis of diabetes (n = 1983), 27.0% were treated with insulin (11.8% with only insulin), 50.8% with a biguanide, 21.7% with a sulfonylurea, 15.4% with a dipeptidyl peptidase-4 (DPP-4) inhibitor, 4.5% with an alpha glucosidase inhibitor, 1.1% with a glucagon-like peptide 1 receptor agonist, and 0.6% with a thiazolidinedione. The proportion of patients with known diabetes receiving no glucose-lowering treatment was 20.3%. These percentages were slightly different when the total of patients with known or unknown diabetes (n = 2137) was used as the denominator ( Table 3 ).
Discussion
DAPA-HF is one of the two large mortality/morbidity trials evaluating the effects of a SGLT2 inhibitor in outpatients with HFrEF. 10 well as with a history of diabetes. 10, 22 Consistent with this, the majority (58%) of patients enrolled in DAPA-HF did not have known diabetes. The proportion with an existing diagnosis of diabetes (42%) was similar to that in contemporary registries but somewhat larger than in the comparator HFrEF trials. [11] [12] [13] [14] [15] [16] [17] 21 The patients randomized in DAPA-HF were also broadly similar, in other respects, to those in the recent registries, although, as has been recognized previously, atrial fibrillation was less frequent in Asian patients. [11] [12] [13] [14] [15] [16] [17] Patients in DAPA-HF were also generally similar to those in the comparator trials with globally diverse enrolment (particularly PARADIGM-HF and ATMOSPHERE), taking account of specific inclusion and exclusion criteria and other issues such as the cessation of randomization of patients with diabetes part-way through recruitment in ATMOSPHERE. 23 One of the few exceptions included the fraction obese, which was larger in DAPA-HF, in keeping with higher prevalence of diabetes and hypertension in DAPA-HF. The worse kidney function in DAPA-HF probably also reflects the slightly older age and high prevalence of diabetes and hypertension in the current trial, as well as the very high rate of use of renin-angiotensin-aldosterone system blockers, including an MRA in 71% of patients (see below). The high frequency of renal dysfunction in COMMANDER-HF is also consistent with this interpretation. 21 Three other differences of note include: (i) the low rate of use of digoxin, (ii) the higher use of devices, especially an ICD than in the other trials, and (iii) the lower proportion (47%) of patients with a prior HF hospitalization. The low use of digoxin probably reflects a historical decline related to the availability of alternative therapeutic options, as well as safety concerns about digoxin; digoxin use was also low in the CHAMP-HF registry. 13, 14, 24 The higher rate of ICD/CRT-D use in DAPA-HF, compared with PARADIGM-HF, however seems to be wholly accounted for by the regional distribution of patients in the two trials, and reflects the higher rate of implantation of these devices in North America and Europe, compared with other geographical areas. This variation likely reflects economic restrictions and is similar to that seen for new (and more costly) pharmacological therapies (see below).
The percentage of patients in the ESC Long-Term Registry with a history of HF hospitalization was also 47%. The fraction with such an admission in the prior 12 months was 27% in DAPA-HF and 38% in CHAMP-HF. These lower rates than historically reported may reflect changing practice aimed at avoiding admission and, also, the effectiveness of modern HF therapies used in combination. 25 Our finding that approximately 70% of patients without a prior diagnosis of diabetes had previously undiagnosed diabetes or pre-diabetes is in keeping with the only other analyses of this type we know of from PARADIGM-HF and GISSI-HF, although in these other reports only a single baseline HbA1c was available. 26, 27 Part of the hypothesis for using SGLT2 inhibitors in HFrEF patients not known to have diabetes is that glucose lowering may also be beneficial in patients with pre-diabetes and may delay or prevent the development of diabetes, and the present findings show that we will be able to test this theory in DAPA-HF. 10 Comparison of patients with a normal HbA1c, pre-diabetes and any diabetes (existing diagnosis and undiagnosed combined) is therefore of some interest. Patients with diabetes were older than those with a normal HbA1c and had worse symptoms and quality of life, despite a similar LVEF and proportion with a history of HF hospitalization. Patients with diabetes did, however, have a higher NT-proBNP level and more often had an ischaemic aetiology (and other manifestations of coronary artery disease) than participants with a normal HbA1c. Patients with pre-diabetes generally exhibited findings intermediate between these two ends of the spectrum, illustrating that 'non-diabetic' patients in prior trials are a heterogeneous group, with clearly worse HF status in patients with dysglycaemia compared to those who are euglycaemic.
Certain co-morbidities, however, were distinctly more common just in those with diabetes, particular obesity, hypertension (whether as history or as determined by measurement of blood pressure), sleep apnoea (which might relate to obesity, if predominantly obstructive in type), renal impairment, anaemia and neuropathy. The triad of diabetes, chronic kidney disease and anaemia (sometimes referred to as the 'cardiorenal-anaemia syndrome') is associated with particularly poor outcomes in HF. 28 A particularly important consideration in any trial evaluating a new, incremental, therapy is the adequacy of background treatment. In DAPA-HF, rates of use of conventional therapy were high, comparing favourably with other trials and, especially, 'real-world' cohorts. The ESC Long-Term Registry reported use of an ACE inhibitor or ARB in 92%, a beta-blocker in 93% and an MRA in 68% of 4792 patients with HFrEF. 11, 12 However, in the recent CHAMP-HF registry from the USA, these rates were much lower: 73%, 83% and 33%, respectively, despite the patients having a similar mean age and LVEF, and lower percentage of patients with chronic kidney disease, than those in DAPA-HF. 13, 14, 28 This may explain the higher median baseline NT-proBNP level in CHAMP-HF (2013 vs. 1437 pg/mL), lower KCCQ overall summary score (62 vs. 68) and smaller fraction with an eGFR < 60 mL/min/1.73 m 2 (26% vs. 41%), compared with DAPA-HF. In CHAMP-HF, more comprehensive therapy was associated with much lower NT-proBNP levels and lower eGFR. 13, 14, 28 Looking at novel HFrEF therapies, only 11% of patients in DAPA-HF were treated with the angiotensin receptor-neprilysin inhibitor combination, sacubitril/valsartan, a finding consistent with the 13% receiving this therapy in the recent CHAMP-HF registry mentioned above. 13, 14, 29 However, the percentage treated with sacubitril/valsartan varied widely in DAPA-HF, from 32% in North America and 25% in Western Europe to 7% or less in other regions, perhaps reflecting different economic circumstances and health service provision. Ivabradine was also little used in recent trials and registries. Sacubitril/valsartan is of particular interest in patients with dysglycaemia as neprilysin is reported to metabolise glucagon-like peptide-1 and neprilysin inhibition to reduce HbA1c and need for insulin in HFrEF patients with diabetes. 30 We found identical rates of use of all key HFrEF therapies in patients with and without diabetes. Indeed, although the proportion of diabetes patients in DAPA-HF with chronic kidney disease was striking (46% of patients with diabetes), the use of ACE inhibitors, ARBs and MRAs was as high in the other patient subgroups in the trial. These findings are consistent with reports from PARADIGM-HF, SHIFT and the ESC Long-Term Registry and encouraging, given prior observations of underuse of these . life-saving treatments because of misplaced concerns about their use in patients with renal dysfunction. 26, 31, 32 Another interesting comparison is a very large registry which included US (n = 28 877) and Asian (n = 2235) patients with both HFrEF and diabetes. 33 There was a gradient in use of treatment from low-income Asian countries, through high-income Asian countries to the USA: ACE inhibitor or ARB use 68.5% to 76.6% and beta-blocker use 68.3% to 90.5%; MRA use was not reported. Regarding anti-hyperglycaemic therapy, most patients with a history of type 2 diabetes in DAPA-HF were treated with oral glucose-lowering therapy (oral therapy only in 53%), insulin (insulin alone in 12%) or both (15%), with 20% of patients receiving no glucose-lowering therapy, findings consistent with other studies. Specifically, in the ESC Long-Term Registry, 28% of patients were not receiving glucose-lowering therapy and in the US/Asian cohort study mentioned earlier, 30-40% of patients with HFrEF were not receiving glucose-lowering treatment, similar to the percentage in PARADIGM-HF. 26, 32 About a fifth of patients with type 2 diabetes were not treated with pharmacological glucose-lowering therapy in other registries, diabetes trials and HF studies. [34] [35] [36] There are few detailed descriptions of the classes of oral glucose-lowering therapies prescribed for patients with HFrEF but in the reports available, the pattern is similar to what we observed in DAPA-HF -with metformin, sulfonylureas and DPP-4 inhibitors accounting for the large majority of these. However, what was different among the studies was the fraction of patients treated with insulin, which varied in the prior reports from 44% in the USA to 24% in Asia; in PARADIGM-HF the proportion was 25% and in SHIFT 32%. This pattern of greater use of insulin in North America, to treat type 2 diabetes, has been reported previously. 26, [30] [31] [32] [33] 37 Consequently, DAPA-HF will test the potential incremental efficacy (and safety) of dapagliflozin, not only in addition to comprehensive disease-modifying pharmacotherapy for HFrEF but also in addition to insulin, conventional non-insulin anti-hyperglycaemic therapies and dietary management of type 2 diabetes. 38 In summary, DAPA-HF has enrolled patients with and without diabetes who have persisting symptoms, a reduced LVEF and an elevated NT-proBNP level, who are similar to those enrolled in contemporary HFrEF registries and randomized in other recent HFrEF trials. The high prevalence of obesity, type 2 diabetes and pre-diabetes, and chronic kidney disease in these patients emphasises the 'cardiometabolic' profile of HFrEF and the potential for SGLT2 inhibition to improve outcomes through glycaemic, renal and other mechanisms.
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